These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37899191)

  • 1. [Novel treatment strategies for acquired thrombotic thrombocytopenic purpura].
    Matsumoto M
    Rinsho Ketsueki; 2023; 64(9):1124-1130. PubMed ID: 37899191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023.
    Matsumoto M; Miyakawa Y; Kokame K; Ueda Y; Wada H; Higasa S; Yagi H; Ogawa Y; Sakai K; Miyata T; Morishita E; Fujimura Y;
    Int J Hematol; 2023 Nov; 118(5):529-546. PubMed ID: 37689812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advances in the treatment of thrombotic thrombocytopenic purpura].
    Uchihara M; Kubo M; Matsumoto M
    Rinsho Ketsueki; 2024; 65(6):567-575. PubMed ID: 38960658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment strategy for patients with thrombotic thrombocytopenic purpura].
    Yagi H
    Rinsho Ketsueki; 2021; 62(8):1222-1228. PubMed ID: 34497210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura.
    Kubo M; Matsumoto M
    Int J Hematol; 2023 Mar; 117(3):331-340. PubMed ID: 36757521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis and treatment of thrombotic thrombocytopenic purpura].
    Kubo M; Matsumoto M
    Rinsho Ketsueki; 2020; 61(5):529-535. PubMed ID: 32507820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathogenesis and novel treatment of thrombotic thrombocytopenic purpura].
    Matsumoto M
    Rinsho Ketsueki; 2021; 62(5):480-485. PubMed ID: 34248125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
    Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
    N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.
    Furlan M; Robles R; Solenthaler M; Lämmle B
    Blood; 1998 Apr; 91(8):2839-46. PubMed ID: 9531594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
    Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
    Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE; Moake JL; Miyata T; George JN
    Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The frontline of TMA management].
    Saito K; Matsumoto M
    Rinsho Ketsueki; 2022; 63(5):463-470. PubMed ID: 35662172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refining the standard of care in immune thrombotic thrombocytopenic purpura.
    Laurence J
    Clin Adv Hematol Oncol; 2024 Oct; 22(8):381-391. PubMed ID: 39356816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates.
    Peyvandi F; Mannucci PM; Valsecchi C; Pontiggia S; Farina C; Retzios AD
    Am J Hematol; 2013 Oct; 88(10):895-8. PubMed ID: 23813910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.
    Abdelgawwad MS; Cao W; Zheng L; Kocher NK; Williams LA; Zheng XL
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2731-2743. PubMed ID: 30354235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelets: thrombotic thrombocytopenic purpura.
    George JN; Sadler JE; Lämmle B
    Hematology Am Soc Hematol Educ Program; 2002; ():315-34. PubMed ID: 12446430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
    Furlan M; Robles R; Morselli B; Sandoz P; Lämmle B
    Thromb Haemost; 1999 Jan; 81(1):8-13. PubMed ID: 10348715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura.
    Dane K; Chaturvedi S
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):539-547. PubMed ID: 30504355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombotic thrombocytopenic purpura.
    Joly BS; Coppo P; Veyradier A
    Blood; 2017 May; 129(21):2836-2846. PubMed ID: 28416507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.
    Mori Y; Wada H; Gabazza EC; Minami N; Nobori T; Shiku H; Yagi H; Ishizashi H; Matsumoto M; Fujimura Y
    Transfusion; 2002 May; 42(5):572-80. PubMed ID: 12084165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.